Tumor Mutation Burden and Efficacy of Nivolumab Monotherapy and in Combination With Ipilimumab in Small Cell Lung Cancer

Durable responses and encouraging survival have been demonstrated with immune checkpoint inhibitors in small cell lung cancer (SCLC), but predictive markers are unknown. We used whole exome sequencing to evaluate the impact of tumor mutation burden (TMB) on efficacy of nivolumab monotherapy or combi...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer Cell
Autors principals: Hellmann, Matthew D., Callahan, Margaret K., Awad, Mark M., Calvo, Emiliano, Ascierto, Paolo A., Atmaca, Akin, Rizvi, Naiyer A., Hirsch, Fred R., Selvaggi, Giovanni, Szustakowski, Joseph D., Sasson, Ariella, Golhar, Ryan, Vitazka, Patrik, Chang, Han, Geese, William J., Antonia, Scott J.
Format: Artigo
Idioma:Inglês
Publicat: 2018
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6750707/
https://ncbi.nlm.nih.gov/pubmed/29731394
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ccell.2018.04.001
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars